R&D Views & Analysis | pharmaphorum

Monday 2 November 2026

Views & Analysis

Views & Analysis

Innovation boosts R&D outlook despite COVID difficulties

Innovation boosts R&D outlook despite COVID difficulties – r...

Ayming Group’s second annual International Innovation Barometer (IIB) has said that the international outlook for R&D is “remarkably promising” despite strong headwinds caused by COVID-

Views & Analysis

Flying the flag for research in Aarskog syndrome

Flying the flag for research in Aarskog syndrome

Delayed diagnosis, lack of awareness, and a limited evidence base – Aarskog syndrome faces all the challenges of rare diseases everywhere.

Views & Analysis

Neale Belson

Pharma’s response to COVID: GSK

A few months into the pandemic, the world is now moving beyond managing the crisis, with more focus on addressing the collateral damages and shaping the future.

R&D

AP_podcast

The Alderley Park Discovery Podcast: COVID testing and the L...

Alderley Park’s Mereside campus is at the forefront of the UK’s COVID-19 testing plans, playing a key role in the national Lighthouse Lab programme.

Views & Analysis

Holistic immunology: Supporting patients at every stage of their journey

Holistic immunology: Supporting patients at every stage of t...

As part of our series from leaders at Janssen, the company’s Max Pahlow looks at how approaches

Views & Analysis

AstraZeneca (AZ)

A history of AstraZeneca

A look back at AstraZeneca and its roots in the UK and Sweden